bioMérieux Shares Dip 1.13% at Close Due to Technical Resistance
bioMérieux shares closed on Wednesday, January 7th at 113.50 euros, marking a decline of 1.13% from the previous day, facing technical resistance at 114.80 euros.
bioMérieux's stock ended the trading session on Wednesday, January 7th at 113.50 euros, down by 1.13% compared to the previous day. The in vitro diagnostics specialist's shares moved in limited volumes, with only 0.17% of the capital traded, indicating investor caution. The stock encountered resistance at its technical threshold of 114.80 euros and failed to break through this level despite recent upward trends. Over the past seven days, bioMérieux has still managed a gain of 3.09%, driven by momentum that began in late December. This consolidation occurs in a context where the stock remains under medium-term pressure. With a 200-day moving average at 115.62 euros, the price remains below this long-term benchmark, indicating a still fragile trajectory. Conversely, a clear crossing of the 50-day (108.53 euros) and 20-day (108.45 euros) moving averages confirms the technical recovery that began in recent weeks.
Market Indicators and Fundamental Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The RSI, set at 81, places the stock in a distinctly overbought zone, reflecting rapid accumulation that could justify a technical pause or a corrective movement. This indicator suggests that recent buyers have taken significant positions, which may temporarily limit immediate upward potential. Meanwhile, the MACD remains positive with a line at 1.33 and a signal at 0.77, confirming that there is still active bullish momentum, although the dynamic could lose steam. On the fundamental side, bioMérieux revised its 2025 growth forecasts downward last November following a disappointing third quarter, but Invest Securities upgraded its recommendation to 'buy' with a target price of 124 euros on November 10th, representing a potential upside of 9.3% from the current price. The company continues to face headwinds, particularly in China and in the respiratory segment, but analysts are banking on the execution of the strategic plan to support profitability.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
